These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 3513779)

  • 1. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals.
    Takeyama K; Minato H; Nakatsuji K; Suzuki H; Nose I; Oka M; Hosoki K; Hatano N; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):69-73. PubMed ID: 3513779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
    Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alacepril on renin-angiotensin-aldosterone system and kallikrein-kinin-prostaglandin system in experimental animals.
    Hosoki K; Takeyama K; Minato H; Fukuya F; Kawahara S; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):77-83. PubMed ID: 3006712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
    Nambu K; Matsumoto K; Takeyama K; Hosoki K; Miyazaki H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):47-51. PubMed ID: 3006710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
    Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive mechanism of alacepril: effect on norepinephrine-induced vasoconstrictive response in vitro and in vivo.
    Takeyama K; Minato H; Ikeno A; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):74-7. PubMed ID: 3513780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
    Matsuno Y; Hori H; Oka M; Nakamura H; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension.
    Mizuno K; Hashimoto S; Kunii N; Tani M; Niimura S; Yabe R; Watari H; Fukuchi S
    Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):175-87. PubMed ID: 2997886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of protein conjugate of desacetyl-alacepril and its effect on angiotensin converting enzyme in renal hypertensive rats.
    Matsumoto K; Nambu K; Fujii T; Takeyama K; Miyazaki H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):52-4. PubMed ID: 3006711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal effects of alacepril in essential hypertension.
    Tomita K; Nonoguchi H; Terada Y; Marumo F
    J Cardiovasc Pharmacol; 1992 Oct; 20(4):520-4. PubMed ID: 1280705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
    Hayashi N; Yamamoto S; Kometani M; Nakao K
    Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
    Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
    Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic analysis of renal protection by angiotensin converting enzyme inhibitor in Dahl salt-sensitive rats.
    Hirawa N; Uehara Y; Kawabata Y; Ohshima N; Ono H; Nagata T; Gomi T; Ikeda T; Goto A; Yagi S
    J Hypertens; 1994 Aug; 12(8):909-18. PubMed ID: 7814850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
    Sakatani A; Miyagawa Y; Takemura N
    J Vet Cardiol; 2016 Sep; 18(3):248-254. PubMed ID: 27364087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and metabolism of the novel antihypertensive agent alacepril in rats.
    Matsumoto K; Miyazaki H; Fujii T; Yoshida K; Amejima H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):40-6. PubMed ID: 3513776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal function following sea snake venom (Lapemis hardwicki) administration in dogs treated with sodium bicarbonate solution.
    Sakwiwatkul K; Chaiyabutr N; Sitprija V
    J Nat Toxins; 2002 May; 11(2):111-21. PubMed ID: 12009111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of long-term converting-enzyme inhibition in renal hypertensive rats.
    Salom MG; Salazar FJ; Fenoy FJ; Pinilla JM; Marín N; Quesada T
    Rev Esp Fisiol; 1990 Jun; 46(2):171-6. PubMed ID: 2274701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive mechanism of alacepril. Effects of its metabolites on the peripheral sympathetic nervous system.
    Minato H; Hosoki K; Hayashi K; Sawayama T; Kadokawa T; Hashimoto M
    Arzneimittelforschung; 1989 Mar; 39(3):319-24. PubMed ID: 2547387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of aprotinin-induced kallikrein inhibition on the cardiovascular and renal action of captopril in diuretic-treated dogs.
    Vemulapalli S; Chiu PJ
    Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):109-23. PubMed ID: 6191727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.